切换至 "中华医学电子期刊资源库"
高级检索
中华肝脏外科手术学电子杂志

中华肝脏外科手术学电子杂志 ›› 2019, Vol. 08 ›› Issue (01) : 72 -75. doi: 10.3877/cma.j.issn.2095-3232.2019.01.017

所属专题： 文献；

基础研究

TFAP 4在肝细胞癌中表达及其与预后的关系
黄涛1, 沈露俊1, 陈奇峰1, 李旺1, 吴沛宏1,†()   
  1. 1. 510060　广州，中山大学肿瘤防治中心微创介入科　华南肿瘤学国家重点实验室　肿瘤医学协同创新中心
  • 收稿日期:2018-10-25 出版日期:2019-02-10
  • 通信作者: 吴沛宏
  • 基金资助:
    广东省公益研究与能力建设专项资金项目(2014A020212532)

TFAP 4 expression in hepatocellular carcinoma and its relationship with clinical prognosis

Tao Huang1, Lujun Shen1, Qifeng Chen1, Wang Li1, Peihong Wu1,†()   

  1. 1. Department of Minimally Invasive Intervention, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
  • Received:2018-10-25 Published:2019-02-10
  • Corresponding author: Peihong Wu
  • About author:
    Corresponding author: Wu Peihong, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

黄涛, 沈露俊, 陈奇峰, 李旺, 吴沛宏. TFAP 4在肝细胞癌中表达及其与预后的关系[J/OL]. 中华肝脏外科手术学电子杂志, 2019, 08(01): 72-75.

Tao Huang, Lujun Shen, Qifeng Chen, Wang Li, Peihong Wu. TFAP 4 expression in hepatocellular carcinoma and its relationship with clinical prognosis[J/OL]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2019, 08(01): 72-75.

目的

探讨转录因子激活增强子结合蛋白4（TFAP 4）在肝细胞癌（HCC）中的表达及其与患者预后的关系。

方法

标本来源于2007年12月至2014年12月中山大学肿瘤防治中心的116例术后病理检查确诊为HCC患者。患者均签署知情同意书，符合医学伦理学规定。其中男103例，女13例；年龄22～75岁，中位年龄44岁。免疫组化法检测HCC组织TFAP 4的表达量，TFAP 4蛋白表达与临床病理参数之间的关系分析采用χ2检验。生存分析采用Kaplan-Meier曲线和Log-rank检验。Cox比例风险回归模型分析TFAP 4在HCC组织中的表达与预后的关系。

结果

TFAP 4高表达者54例，低表达者62例，其表达与患者临床病理参数无相关性（P>0.05）。TFAP 4高表达患者的无瘤生存和总体生存均更差（χ2=11.030，4.269；P<0.05）。Cox回归分析显示，HBsAg阳性是影响HCC患者无瘤生存的独立危险因素（HR=4.722，95%CI：1.469～19.446，P<0.05），而TFAP 4高表达是影响HCC患者无瘤生存和总体生存的独立危险因素（HR=2.437，2.598；95%CI：1.352～4.394，1.036～6.515；P<0.05）。

结论

TFAP 4高表达是影响HCC患者无瘤生存和总体生存的独立危险因素，TFAP 4高表达患者预后较差。TFAP 4可作为判断HCC患者预后的生物学标志物。

关键词: 癌，肝细胞, TFAP4, 预后, 免疫组织化学
Objective

To investigate the expression of transcription factor activating enhancer-binding protein 4 (TFAP 4) in hepatocellular carcinoma (HCC) and its relationship with the clinical prognosis of HCC patients.

Methods

The tissue specimens were obtained from 116 HCC patients diagnosed by pathological examination in Sun Yat-sen University Cancer Center from December 2007 to December 2014. The informed consents of all patients were obtained and the local ethical committee approval was received. Among 116 patients, 103 were male and 13 were female, aged 22-75 years with a median age of 44 years. The expression of TFAP 4 in HCC tissues was measured by immunohistochemical staining. The relationship between the expression of TFAP 4 protein and clinicopathological parameters was analyzed by Chi-square test. The survival analysis was conducted by Kaplan-Meier survival curve and Log-rank test. The relationship between TFAP 4 expression and clinical prognosis of HCC patients was analyzed by Cox's proportional hazards model.

Results

TFAP 4 was highly expressed in 54 patients and lowly expressed in 62. The expression of TFAP 4 was not associated with clinicopathological features (P>0.05). The tumor-free survival and overall survival of patients with high expression of TFAP 4 were worse than those with low expression of TFAP 4 (χ2=11.030, 4.269; P<0.05). Cox's regression analysis demonstrated that positive HBsAg was an independent risk factor for the tumor-free survival of HCC patients (HR=4.722, 95%CI: 1.469-19.446, P<0.05), whereas high expression of TFAP 4 was an independent risk factor for tumor-free survival and overall survival of HCC patients (HR=2.437, 2.598; 95%CI: 1.352-4.394, 1.036-6.515; P<0.05).

Conclusions

High expression of TFAP 4 is an independent risk factor for tumor-free survival and overall survival of HCC patients. Patients with high expression of TFAP 4 have poorer clinical prognosis. TFAP 4 can be used as a biomarker to predict the clinical prognosis of HCC patients.

Key words: Carcinoma, hepatocellular, TFAP4, Prognosis, Immunohistochemistry
表1 TFAP4在HCC中的表达与临床病理参数的关系（例）
参数 例数 TFAP 4表达 χ2值 P值
高表达 低表达
年龄 ? ? ? 0.417 0.518
? < 60岁 96 46 50 ? ?
? ≥60岁 20 8 12 ? ?
性别 ? ? ? 3.243 0.072
? 男 103 51 52 ? ?
? 女 13 3 10 ? ?
HBsAg ? ? ? 0.231 0.631
? 阴性 17 7 10 ? ?
? 阳性 99 47 52 ? ?
AFP ? ? ? 2.260 0.133
? < 400 μg/L 81 34 47 ? ?
? ≥400 μg/L 35 20 15 ? ?
肿瘤直径 ? ? ? ? ?
? < 5 cm 72 35 37 0.324 0.569
? ≥5 cm 44 19 25 ? ?
肝包膜 ? ? ? 1.724 0.189
? 未侵犯 78 33 45 ? ?
? 侵犯 38 21 17 ? ?
脉管侵犯 ? ? ? 3.346 0.067
? 无 105 46 59 ? ?
? 有 11 8 3 ? ?
BCLC分期 ? ? ? 0.718 0.397
? A期 102 46 56 ? ?
? B期 14 8 6 ? ?
病理分级 ? ? ? 0.327 0.568
? Ⅰ～Ⅱ级 99 45 54 ? ?
? Ⅲ～Ⅳ级 17 9 8 ? ?
图1 TFAP 4的表达与HCC患者预后的Kaplan-Meier生存曲线
[1]
Petrick JL, Braunlin M, Laversanne M, et al. International trends in liver cancer incidence, overall and by histologic subtype, 1978-2007[J]. Int J Cancer, 2016, 139(7):1534-1545.
[2]
European Association for the Study of the Liver, European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1):182-236.
[3]
Fan ST, Mau Lo C, Poon RT, et al. Continuous improvement of survival outcomes of resection of hepatocellular carcinoma: a 20-year experience[J]. Ann Surg, 2011, 253(4):745-758.
[4]
Jeon Y, Kim H, Jang ES, et al. Expression profile and prognostic value of glypican-3 in post-operative South Korean hepatocellular carcinoma patients[J]. APMIS, 2016, 124(3):208-215.
[5]
Li D, Mallory T, Satomura S. AFP-L3: a new generation of tumor marker for hepatocellular carcinoma[J]. Clin Chim Acta, 2001, 313(1/2):15-19.
[6]
Mao Y, Yang H, Xu H, et al. Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma[J]. Gut, 2010, 59(12):1687-1693.
[7]
Marrero JA, Feng Z, Wang Y, et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma[J]. Gastroenterology, 2009, 137(1):110-118.
[8]
Stefaniuk P, Cianciara J, Wiercinska-Drapalo A. Present and future possibilities for early diagnosis of hepatocellular carcinoma[J]. World J Gastroenterol, 2010, 16(4):418-424.
[9]
Jones S. An overview of the basic helix-loop-helix proteins[J]. Genome Biol, 2004, 5(6):226.
[10]
Jackstadt R, Röh S, Neumann J, et al. AP4 is a mediator of epithelial-mesenchymal transition and metastasis in colorectal cancer[J]. J Exp Med, 2013, 210(7):1331-1350.
[11]
Xinghua L, Bo Z, Yan G, et al. The overexpression of AP-4 asa prognostic indicator for gastric carcinoma[J]. Med Oncol, 2012, 29(2):871-877.
[12]
Wei J, Yang P, Zhang T, et al. Overexpression of transcription factor activating enhancer binding protein 4 (TFAP4) predicts poor prognosis for colorectal cancer patients[J]. Exp Ther Med, 2017, 14(4):3057-3061.
[13]
Chen C, Cai Q, He W, et al. AP4 modulated by the PI3K/AKT pathway promotes prostate cancer proliferation and metastasis of prostate cancer via upregulating L-plastin[J]. Cell Death Dis, 2017, 8(10):e3060.
[14]
Gong H, Han S, Yao H, et al. AP4 predicts poor prognosis in non-small cell lung cancer[J]. Mol Med Rep, 2014, 10(1):336-340.
[15]
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132.
[16]
Johnson PJ. The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma[J]. Clin Liver Dis, 2001, 5(1):145-159.
[17]
Jung P, Menssen A, Mayr D, et al. AP4 encodes a c-MYC-inducible repressor of p21[J]. Proc Natl Acad Sci, 2008, 105(39):15046-15051.
[18]
Kouraklis G, Katsoulis IE, Theocharis S, et al. Does the expression of cyclin E, pRb, and p21 correlate with prognosis in gastric adenocarcinoma?[J]. Dig Dis Sci, 2009, 54(5):1015-1020.
[19]
Wang L, Meng Y, Xu JJ, et al. The transcription factor AP4 promotes oncogenic phenotypes and cisplatin resistance by regulating LAPTM4B expression[J]. Mol Cancer Res, 2018, 16(5):857-868.
[20]
Chen S, Chiu SK. AP4 activates cell migration and EMT mediated by p53 in MDA-MB-231 breast carcinoma cells[J]. Mol Cell Biochem, 2015, 407(1/2):57-68.
[1] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[2] 李华志, 曹广, 刘殿刚, 张雅静. 不同入路下行肝切除术治疗原发性肝细胞癌的临床对比[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 52-55.
[3] 常小伟, 蔡瑜, 赵志勇, 张伟. 高强度聚焦超声消融术联合肝动脉化疗栓塞术治疗原发性肝细胞癌的效果及安全性分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 56-59.
[4] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[5] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[6] 梁孟杰, 朱欢欢, 王行舟, 江航, 艾世超, 孙锋, 宋鹏, 王萌, 刘颂, 夏雪峰, 杜峻峰, 傅双, 陆晓峰, 沈晓菲, 管文贤. 联合免疫治疗的胃癌转化治疗患者预后及术后并发症分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 619-623.
[7] 张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[8] 公宇, 廖媛, 尚梅. 肝细胞癌TACE术后复发影响因素及预测模型建立[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 818-824.
[9] 李一帆, 朱帝文, 任伟新, 鲍应军, 顾俊鹏, 张海潇, 曹耿飞, 阿斯哈尔·哈斯木, 纪卫政. 血GP73水平在原发性肝癌TACE疗效评价中的作用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 825-830.
[10] 刘敏思, 李荣, 李媚. 基于GGT与Plt比值的模型在HBV相关肝细胞癌诊断中的作用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 831-835.
[11] 关小玲, 周文营, 陈洪平. PTAAR在乙肝相关慢加急性肝衰竭患者短期预后中的预测价值[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 841-845.
[12] 董佳, 王坤, 张莉. 预后营养指数结合免疫球蛋白、血糖及甲胎蛋白对HBV 相关慢加急性肝衰竭患者治疗后预后不良的预测价值[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 555-559.
[13] 王景明, 王磊, 许小多, 邢文强, 张兆岩, 黄伟敏. 腰椎椎旁肌的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 846-852.
[14] 谭瑞义. 小细胞骨肉瘤诊断及治疗研究现状与进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 781-784.
[15] 郭曌蓉, 王歆光, 刘毅强, 何英剑, 王立泽, 杨飏, 汪星, 曹威, 谷重山, 范铁, 李金锋, 范照青. 不同亚型乳腺叶状肿瘤的临床病理特征及预后危险因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 524-532.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号